229 related articles for article (PubMed ID: 33317068)
1. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
2. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
4. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
Wright L; Barril X; Dymock B; Sheridan L; Surgenor A; Beswick M; Drysdale M; Collier A; Massey A; Davies N; Fink A; Fromont C; Aherne W; Boxall K; Sharp S; Workman P; Hubbard RE
Chem Biol; 2004 Jun; 11(6):775-85. PubMed ID: 15217611
[TBL] [Abstract][Full Text] [Related]
6. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors.
Immormino RM; Kang Y; Chiosis G; Gewirth DT
J Med Chem; 2006 Aug; 49(16):4953-60. PubMed ID: 16884307
[TBL] [Abstract][Full Text] [Related]
7. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
[TBL] [Abstract][Full Text] [Related]
9. A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.
Gopalakrishnan R; Matta H; Chaudhary PM
Clin Cancer Res; 2013 Sep; 19(18):5016-26. PubMed ID: 23881928
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
[TBL] [Abstract][Full Text] [Related]
12. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F
Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042
[TBL] [Abstract][Full Text] [Related]
13. Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
Sharp SY; Roe SM; Kazlauskas E; Cikotienė I; Workman P; Matulis D; Prodromou C
PLoS One; 2012; 7(9):e44642. PubMed ID: 22984537
[TBL] [Abstract][Full Text] [Related]
14. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
Jung J; Kwon J; Hong S; Moon AN; Jeong J; Kwon S; Kim JA; Lee M; Lee H; Lee JH; Lee J
Bioorg Med Chem Lett; 2020 Jun; 30(12):127165. PubMed ID: 32305165
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and molecular docking studies of novel pyrazolyl 2-aminopyrimidine derivatives as HSP90 inhibitors.
Mettu A; Talla V; Bajaj DM; Subhashini NJP
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900063. PubMed ID: 31411362
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms.
Xu L; Woodward C; Khan S; Prakash C
Drug Metab Dispos; 2012 Apr; 40(4):680-93. PubMed ID: 22217465
[TBL] [Abstract][Full Text] [Related]
18. Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.
Jiang F; Wang HJ; Jin YH; Zhang Q; Wang ZH; Jia JM; Liu F; Wang L; Bao QC; Li DD; You QD; Xu XL
J Med Chem; 2016 Dec; 59(23):10498-10519. PubMed ID: 27933959
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of 5,6-dihydro-4H-benzo[d]isoxazol-7-one and 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-one derivatives as potential Hsp90 inhibitors.
Musso L; Cincinelli R; Giannini G; Manetti F; Dallavalle S
Chem Biol Drug Des; 2015 Nov; 86(5):1030-5. PubMed ID: 25855505
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]